drugset / Trial / NCT04378010

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

NCT04378010

Phase 2 Terminated 98 enrolled Enanta Pharmaceuticals, Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

Timeline

Start
2020-01-27
Primary completion
2021-10-04
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP-305 Unknown 1.5 mg Oral
Subject EDP-305 Unknown 2 mg Oral